The purpose of this core is to provide 'state of the art' proteomic support for projects 1, 3 and 4, Drs. J. Zheng, T. Ikezu and H. Gendelman. Biomarkers will be characterized, including known and novel secretory factors produced from macrophages, microglia and/or neurons that contribute to neurodegenerative and/or neuroregenerative activities during disease. Specifically, biological fluids obtained from conditioned media or brain tissue in HIV-1 encephalitis severe combined immunodeficiency disease (SCID) and the Alzheimer's Disease (AD) mice will be evaluated. Proteins contained within samples will be identified (semi-quantitatively) and its chemical profile deciphered by Ciphergen's ProteinChip technology utilizing commercially produced chip arrays. These chips will contain a variety of surface coatings, includinghydrophobic, hydrophilic, anion, cation, metal binding and preactivated surfaces to enhance detection. Once the target biomarker has been identified, the target protein will be purified using the Amersham Pharmacia Biotech AKTA fast protein liquid chromatography (FPLC) system. The Center for Neurovirology and Neurodegenerative Disorders (CNND) has a Proteomics Core for its exclusive use. This facility houses both a complete Ciphergen's ProteinChip and a Amersham Pharmacia Biotech, AKTA FPLC system. In addition to these one- and two-dimensional (1- and 2-D) gel electrophoresis and a high performance liquid chromatography (HPLC) facilities are within the core facility.
Olson, Katherine E; Bade, Aditya N; Namminga, Krista L et al. (2018) Persistent EcoHIV infection induces nigral degeneration in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice. J Neurovirol 24:398-410 |
Schutt, Charles R; Gendelman, Howard E; Mosley, R Lee (2018) Tolerogenic bone marrow-derived dendritic cells induce neuroprotective regulatory T cells in a model of Parkinson's disease. Mol Neurodegener 13:26 |
Thomas, Midhun B; Gnanadhas, Divya Prakash; Dash, Prasanta K et al. (2018) Modulating cellular autophagy for controlled antiretroviral drug release. Nanomedicine (Lond) 13:2139-2154 |
Kiyota, Tomomi; Machhi, Jatin; Lu, Yaman et al. (2018) URMC-099 facilitates amyloid-? clearance in a murine model of Alzheimer's disease. J Neuroinflammation 15:137 |
Kevadiya, Bhavesh D; Woldstad, Christopher; Ottemann, Brendan M et al. (2018) Multimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution. Theranostics 8:256-276 |
McMillan, JoEllyn; Szlachetka, Adam; Slack, Lara et al. (2018) Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques. Antimicrob Agents Chemother 62: |
Sillman, Brady; Woldstad, Christopher; Mcmillan, Joellyn et al. (2018) Neuropathogenesis of human immunodeficiency virus infection. Handb Clin Neurol 152:21-40 |
Zhou, Tian; Su, Hang; Dash, Prasanta et al. (2018) Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials 151:53-65 |
Kevadiya, Bhavesh D; Ottemann, Brendan M; Thomas, Midhun Ben et al. (2018) Neurotheranostics as personalized medicines. Adv Drug Deliv Rev : |
Zhou, Tian; Lin, Zhiyi; Puligujja, Pavan et al. (2018) Optimizing the preparation and stability of decorated antiretroviral drug nanocrystals. Nanomedicine (Lond) 13:871-885 |
Showing the most recent 10 out of 240 publications